Last updated: September 7, 2026
Simeprevir sodium, marketed primarily as Olysio by Janssen and as Sovriad in some markets, was a first-generation direct-acting antiviral for chronic hepatitis C virus infection. Its commercial trajectory was short: sales rose rapidly after its 2013 U.S. launch, peaked in 2014, and declined sharply as all-oral regimens led by sofosbuvir, ledipasvir, velpatasvir, and glecaprevir/pibrentasvir displaced simeprevir-based treatment.
The product no longer has meaningful commercial relevance in the U.S. branded market. Its main business value was realized between 2014 and 2015, before broad adoption of newer pan-genotypic regimens. The principal competitive risk was therapeutic substitution rather than a conventional generic launch.
What is simeprevir sodium and how was it used?
Simeprevir sodium is an NS3/4A protease inhibitor used in combination with other antiviral agents to treat chronic HCV infection. It was not intended as monotherapy.
The FDA approved Olysio in November 2013 for adults with chronic HCV genotype 1 infection in combination with peginterferon alfa and ribavirin. In December 2014, the FDA approved simeprevir with sofosbuvir for genotype 1 infection, including use without interferon and ribavirin in specified patients. The combination was commercially important because it offered a shorter and more tolerable treatment path than interferon-based therapy.[1,2]
Key product facts were:
| Attribute |
Simeprevir sodium |
| Brand |
Olysio; Sovriad |
| Developer |
Medivir AB |
| Commercial rights |
Janssen Pharmaceuticals and affiliated entities |
| Mechanism |
HCV NS3/4A protease inhibition |
| Initial U.S. approval |
November 22, 2013 |
| Initial target |
Chronic HCV genotype 1 |
| Later clinical use |
Primarily with sofosbuvir |
| Dosage form |
Oral capsule |
| Typical dose |
150 mg once daily with food |
| FDA regulatory class |
Small-molecule drug |
| Biosimilar exposure |
Not applicable |
| Current commercial position |
Commercially obsolete in the United States |
Simeprevir had activity against genotype 1 and genotype 4 but was vulnerable to baseline resistance-associated substitutions, especially in genotype 1a patients with the Q80K polymorphism. The FDA label required attention to genotype and resistance factors, which reduced its utility relative to later pan-genotypic products.[1]
How did simeprevir sales develop?
Simeprevir generated rapid but temporary revenue growth. Johnson & Johnson reported Olysio sales of approximately $2.3 billion in 2014, followed by a steep decline as competing direct-acting antivirals gained market share.[3]
| Fiscal year |
Approximate Olysio sales |
Commercial interpretation |
| 2013 |
Less than $0.2 billion |
Partial-year U.S. launch |
| 2014 |
About $2.3 billion |
Peak commercial year |
| 2015 |
About $1.1 billion |
Rapid erosion from newer HCV regimens |
| 2016 |
About $0.3 billion |
Mature decline |
| 2017 |
Less than $0.1 billion |
Residual demand |
| 2018 onward |
Minimal or no material contribution |
Product withdrawal and market replacement |
Janssen’s 2014 performance benefited from strong demand for simeprevir plus sofosbuvir. The market shifted quickly after Gilead Sciences established Sovaldi, Harvoni, and later Epclusa as preferred regimens. AbbVie’s Viekira Pak and Mavyret added further pressure, while Merck’s Zepatier competed in genotype-specific treatment.
Simeprevir’s sales decline was therefore structural. It was not primarily caused by manufacturing constraints, adverse safety findings, or a single patent event. The product lost its position because treatment guidelines increasingly favored regimens with broader genotype coverage, fewer resistance limitations, shorter treatment courses, and simpler prescribing.
When did simeprevir lose exclusivity?
Simeprevir’s U.S. regulatory exclusivity was substantially less important than its clinical obsolescence.
The product received five-year new chemical entity exclusivity from its November 2013 approval. That period generally ran through November 2018, subject to applicable pediatric or regulatory adjustments. By the time conventional generic competition could become commercially relevant, physicians had already shifted toward newer HCV regimens.[1,4]
The practical exclusivity timeline was:
| Event |
Timing |
| U.S. approval |
November 2013 |
| Five-year NCE exclusivity |
Approximately through November 2018 |
| Peak sales |
2014 |
| Major market displacement |
2015-2016 |
| U.S. commercial withdrawal |
Late 2010s |
| FDA withdrawal of approval |
The application was later withdrawn for commercial reasons, not because of a safety or efficacy finding |
The distinction matters. Simeprevir remained protected by intellectual-property rights after its commercial peak, but the value of those rights fell rapidly as treatment protocols changed.
What patents protected simeprevir sodium?
Simeprevir was protected by a portfolio covering the active compound, related macrocyclic HCV protease inhibitors, pharmaceutical compositions, and methods of treatment. The underlying discovery and development program originated with Medivir and was licensed to Janssen’s predecessor organizations.
Publicly available patent records associated with simeprevir and the Olysio product included U.S. patents directed to macrocyclic HCV protease inhibitors and related compositions. The relevant patent estate extended beyond the five-year regulatory exclusivity period, with certain U.S. patent terms reaching into the mid-2020s.[5,6]
The patent categories were:
Composition-of-matter patents
The core patents covered macrocyclic NS3/4A protease inhibitor structures, including the chemical family from which simeprevir was selected. Composition patents generally provided the strongest protection because they could block manufacture or sale of the active pharmaceutical ingredient independent of a particular formulation or treatment regimen.
Pharmaceutical-composition patents
Secondary patents covered formulations and pharmaceutical compositions containing simeprevir or related protease inhibitors. These patents had less strategic value once the commercial product declined, but they could complicate abbreviated new drug application strategies if listed or enforceable against a proposed generic.
Method-of-use patents
Method patents covered treatment of HCV infection with simeprevir, including combination use with peginterferon, ribavirin, and sofosbuvir. Their value depended on prescribing behavior and the scope of induced-infringement theories. Once physicians moved to other regimens, method-of-use claims had limited commercial leverage.
Geographic coverage
The portfolio was filed across major pharmaceutical markets, including the United States, Europe, Japan, and other jurisdictions. Patent duration and enforceability varied by country. Patent-term extensions and supplementary protection certificates could affect the effective protection period outside the United States.
What was the Orange Book status of Olysio?
Olysio was listed in the FDA Orange Book during its commercial period as an approved prescription drug. Orange Book relevance depended on whether a particular patent was listed against the approved drug and whether an ANDA applicant filed a Paragraph IV certification.[4]
Because Olysio was later discontinued and its NDA withdrawn, current Orange Book significance is limited. The product’s historical listing does not create a current market barrier comparable to an actively marketed, high-revenue product.
An ANDA applicant challenging an active listed patent would typically have faced one of four outcomes:
- A Paragraph IV certification alleging that the patent was invalid, unenforceable, or not infringed.
- A Paragraph III certification agreeing to wait until patent expiration.
- A section viii carve-out for a method of use not included in the proposed label.
- No commercial filing because the market opportunity was too small.
For simeprevir, the fourth scenario became increasingly rational as branded demand collapsed.
Were there Paragraph IV challenges or generic settlements?
No major, commercially consequential Paragraph IV campaign comparable to those involving blockbuster drugs such as Sovaldi, Harvoni, or Revlimid defined the simeprevir market.
The absence of a major publicized generic settlement is commercially understandable. A generic manufacturer would have needed to evaluate:
- Remaining patent life;
- The cost of developing and validating the active ingredient;
- Limited future prescribing;
- Competition from low-cost generic and branded pan-genotypic therapies;
- The risk that physicians would not return to a genotype-specific protease inhibitor;
- Potential regulatory complexity associated with combination-use labeling.
The principal generic-launch risk was therefore delayed and economically weak. Any launch after the major DAA transition would have addressed a shrinking residual market rather than the original blockbuster opportunity.
How strong was the simeprevir patent estate?
The estate was technically strong during the product’s commercial window but commercially weak after therapeutic substitution accelerated.
| Strength factor |
Assessment |
| Core compound protection |
Strong during the protected term |
| Formulation protection |
Moderate |
| Method-of-use protection |
Moderate to weak as prescribing shifted |
| Resistance profile |
Commercial disadvantage |
| Regulatory exclusivity |
Expired or no longer commercially relevant |
| Generic threat before 2018 |
Limited by exclusivity and patents |
| Generic threat after 2018 |
Secondary to market substitution |
| Remaining revenue value |
Low |
The most valuable rights were the composition patents. Formulation and method claims could extend the defensive perimeter, but they could not reverse the loss of clinical preference. A patent estate is commercially durable only when physicians continue to use the protected product.
What patent litigation affected simeprevir?
Simeprevir did not produce a litigation profile that materially altered the HCV market. Public attention focused more heavily on patent disputes involving sofosbuvir, ledipasvir, and other major HCV products.
The relevant legal risk for simeprevir involved:
- Potential ANDA litigation against compound or formulation patents;
- Enforcement of combination-treatment claims;
- Patent-term calculations;
- Licensing rights between Medivir and Janssen;
- International validity and infringement disputes.
No widely reported settlement created a meaningful delayed generic-entry event comparable to major pharmaceutical settlements involving larger products. The commercial decline occurred before patent litigation could become the primary determinant of market access.
What licensing deals supported simeprevir?
Medivir discovered simeprevir and licensed rights to Janssen’s predecessor, Tibotec, in the early 2000s. Janssen assumed development, regulatory, and commercialization responsibilities for the product. Medivir received milestone payments and royalties under the collaboration structure.[7]
The transaction had two economic phases:
- Medivir monetized its discovery through licensing, development milestones, and royalties.
- Janssen captured commercial revenue during the short period in which simeprevir was a preferred HCV therapy.
The licensing model reduced Medivir’s need to fund global late-stage development but also limited its direct control over commercial strategy. Janssen controlled positioning, regulatory filings, and market withdrawal decisions in the principal markets.
How did simeprevir compare with competing HCV drugs?
Simeprevir was rapidly overtaken by drugs with broader coverage and simpler treatment protocols.
| Product |
Company |
Main commercial advantage over simeprevir |
| Sovaldi |
Gilead Sciences |
High efficacy and foundational DAA platform |
| Harvoni |
Gilead Sciences |
Once-daily fixed combination for genotype 1 |
| Epclusa |
Gilead Sciences |
Pan-genotypic coverage |
| Viekira Pak |
AbbVie |
Combination approach for genotype 1 |
| Zepatier |
Merck |
Genotype-specific alternative |
| Mavyret |
AbbVie |
Pan-genotypic coverage and shorter treatment |
| Vosevi |
Gilead Sciences |
Salvage treatment after prior DAA failure |
Simeprevir’s disadvantages included genotype restrictions, the Q80K issue in genotype 1a, reliance on combination therapy, and weaker positioning once pan-genotypic regimens became standard. These limitations reduced both pricing power and persistence of demand.
What is the FDA regulatory status of simeprevir?
Simeprevir was FDA-approved, but its commercial status later deteriorated as Janssen discontinued the product. The withdrawal was associated with commercial considerations rather than a finding that the drug was unsafe or ineffective for its approved use.[1,8]
The regulatory history is important for future product analysis:
- The product was approved through the traditional NDA pathway.
- It was not a biologic and does not have biosimilar competition.
- Any successor product would require a conventional small-molecule regulatory strategy.
- A generic applicant would generally use the ANDA pathway, subject to applicable patent certifications and labeling constraints.
- The original clinical value proposition has largely disappeared because HCV treatment standards changed.
What generic entry risks exist for simeprevir?
The technical possibility of generic entry remains distinct from the commercial likelihood of a meaningful launch.
A generic manufacturer could face lower development costs because simeprevir is an established small molecule. The key obstacles are commercial:
- Minimal branded demand;
- Established alternatives with better genotype coverage;
- Potentially low reimbursement;
- Declining physician familiarity;
- Manufacturing economics at low volumes;
- Limited value in developing a product for an obsolete treatment algorithm.
Generic entry could occur in jurisdictions where residual demand remains, patents have expired, and local registration costs are manageable. A U.S. generic launch would likely have limited revenue potential unless pricing or supply conditions created a temporary niche.
What manufacturing and intellectual-property barriers remain?
Simeprevir is a complex macrocyclic molecule. Manufacturing barriers include multi-step synthesis, stereochemical control, impurity management, analytical characterization, and scale-up requirements. These factors can increase cost relative to simpler generic active ingredients.
The manufacturing challenge is not insurmountable. The greater barrier is the return on investment. A company must secure reliable API supply, validate the finished dosage form, complete bioequivalence work, and maintain regulatory filings for a product with limited demand.
Intellectual-property barriers may include residual composition patents in selected countries, process patents, formulation claims, and regulatory exclusivity differences across jurisdictions. Those barriers are more relevant to timing than to long-term commercial value.
What revenue exposure remains for Janssen and Medivir?
For Janssen, simeprevir no longer represents a material revenue exposure relative to the company’s active portfolio. The product’s economic importance ended after the 2014-2015 peak.
For Medivir, simeprevir was historically significant because royalty and milestone income supported the company’s value as a biotechnology licensor. The erosion of simeprevir royalties increased the importance of Medivir’s pipeline and later strategic transactions.
The financial trajectory can be summarized as follows:
| Period |
Revenue status |
Main driver |
| 2013 |
Initial revenue |
U.S. launch |
| 2014 |
Blockbuster revenue |
Strong uptake, limited early competition |
| 2015 |
Sharp decline |
Sofosbuvir-led regimen displacement |
| 2016-2017 |
Residual revenue |
Narrow use and competitive substitution |
| 2018 onward |
Immaterial |
Commercial withdrawal and therapeutic obsolescence |
What are the likely generic launch scenarios?
The most likely scenarios are:
No economically meaningful U.S. generic launch
This is the strongest commercial scenario. Patent expiry alone does not create a viable market when treatment guidelines have moved elsewhere.
Limited regional launch
A generic could be registered in selected countries where HCV treatment access is less standardized, branded supply is unavailable, or price-sensitive buyers use older regimens.
API or technology reuse
The underlying chemistry, process knowledge, or patent disclosures could have value for manufacturers developing related HCV protease inhibitors. This is more likely than a large branded revival.
Late opportunistic entry
A manufacturer could enter after patent expiry with a low-cost product, but the launch would probably target residual demand and would not recreate the 2014 market.
Key Takeaways
- Simeprevir sodium was a commercially successful but short-lived HCV product.
- Olysio sales peaked at approximately $2.3 billion in 2014 and declined sharply thereafter.
- The product was displaced by newer all-oral and pan-genotypic HCV regimens.
- Its U.S. five-year new chemical entity exclusivity ran approximately from 2013 to 2018.
- Composition, formulation, and method-of-use patents extended protection into the mid-2020s in relevant jurisdictions, but patent protection did not preserve commercial demand.
- No major Paragraph IV litigation or settlement shaped the market.
- Biosimilar risk is irrelevant because simeprevir is a small molecule.
- Generic risk is commercially limited because the treatment standard has moved beyond simeprevir.
- Medivir benefited from licensing milestones and royalties, while Janssen captured the principal commercial upside.
- Current revenue exposure for Janssen and Medivir is immaterial relative to the product’s 2014 peak.
FAQs
Is simeprevir still marketed in the United States?
No meaningful U.S. branded market remains. Janssen discontinued Olysio as newer HCV regimens replaced simeprevir-based therapy.
Can simeprevir be used with sofosbuvir?
Simeprevir was approved for combination use with sofosbuvir in certain genotype 1 patients. That regimen was later displaced by simpler pan-genotypic combinations.
Does simeprevir have biosimilar competition?
No. Biosimilar rules apply to biologic products. Simeprevir is a chemically synthesized small molecule, so any competitor would generally use a generic-drug pathway.
Why did simeprevir sales fall so quickly?
Sales fell because physicians adopted newer direct-acting antiviral combinations with broader genotype coverage, fewer resistance limitations, shorter treatment courses, and simpler prescribing.
Does simeprevir still have patent value?
Residual patent value may exist in individual jurisdictions for composition, formulation, or manufacturing claims. Its practical commercial value is low because the market has largely moved to other HCV therapies.
References
- U.S. Food and Drug Administration. (2013). FDA approves Olysio to treat chronic hepatitis C virus infection.
- U.S. Food and Drug Administration. (2014). FDA approves Olysio in combination with Sovaldi for chronic hepatitis C.
- Johnson & Johnson. (2014-2018). Annual reports and Form 10-K filings.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Public Search records for simeprevir-related U.S. patents.
- European Patent Office. (n.d.). Espacenet patent records for simeprevir and macrocyclic HCV protease inhibitors.
- Medivir AB. (2013-2018). Annual reports and regulatory disclosures concerning simeprevir licensing and royalties.
- U.S. Food and Drug Administration. (n.d.). Drug approval package and discontinued drug product records for Olysio.
